Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia | CMAC

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):52-60

​ Edelstein I.A., Rudneva N.S., Romanov A.V., Zubareva L.M., Kuzmenkov A.Yu., Kolesnikova E.A., Trushin I.V., Borisov I.V., Sukhanova L.N., Akhmedova A.M., Novikova O.P., Kozlov R.S.
10.36488/cmac.2022.1.52-60
Mycoplasma genitalium macrolides antimicrobial resistance realtime polymerase chain reaction 23S rRNA mutations
Section
Antimicrobial Resistance
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):52-60

Objective.

To determine spectrum and prevalence of genetic determinants of resistance to macrolides in Mycoplasma genitalium in a Russian patient population.

Materials and Methods.

A total of 873 M. genitalium-positive samples from five geographical regions of Russia were investigated over the period of 2009–2019 using the previously developed protocol of real-time polymerase chain reaction (allows detecting any nucleotide substitutions in the 23S rRNA gene of M. genitalium at positions 2058, 2059, and 2611). The results were confirmed using Sanger sequencing.

Results.

The most frequent mutations associated with resistance to macrolides in M. genitalium were the following: A2058G (60.5%) and A2059G (30.2%). The relatively rare mutations were A2058T (7%) and C2611T (2.3%). In the studied period, there was no trend to increase in frequency of mutations associated with resistance to macrolides. The study results are presented as an open project on the AMRcloud platform (https://amrcloud.net/ru/project/demares/).

Conclusions.

Our data emphasize a need to introduce regular screening of M. genitalium-positive samples for the presence of macrolide resistance-associated mutations into clinical practice.

Inna A. Edelstein

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Rudneva N.S.

Tula Regional Clinical Dermatology and Venerology Dispensary, Tula, Russia

Andrey V. Romanov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Zubareva L.M.

Smolensk Dermatology and Venerology Dispensary, Smolensk, Russia

Kuzmenkov Alexey Yuryevich

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Elena A. Kolesnikova

Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology, Nizhny Novgorod, Russia

Ivan V. Trushin

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Borisov I.V.

Institute of Biochemistry and Physiology of Plants and Microorganisms of the Russian Academy of Sciences, Saratov, Russia

Sukhanova L.N.

Tula Regional Clinical Dermatology and Venerology Dispensary, Tula, Russia

Akhmedova A.M.

Tula Regional Clinical Dermatology and Venerology Dispensary, Tula, Russia

Novikova O.P.

Medical center «Consultant», Tula, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Gnanadurai R., Fifer H. Mycoplasma genitalium: a review. Microbiology. 2020;166(1):21-29. DOI: 10.1099/mic.0.000830
  • 2. Khatib N., Bradbury C., Chalker V., Koh G., Smit E., Wilson S., et al. Prevalence of Trichomonas vaginalis, Mycoplasma genitalium and Ureaplasma urealyticum in men with urethritis attending an urban sexual health clinic. Int J STD AIDS. 2015;26(6):388-392. DOI: 10.1177/0956462414539464
  • 3. Seña A.C., Lee J.Y., Schwebke J., Philip S.S., Wiesenfeld H.C., Rompalo A.M., et al. A silent epidemic: the prevalence, incidence and persistence of Mycoplasma genitalium among young, asymptomatic high-risk women in the United States. Clin Infect Dis. 2018;67(1):73-79. DOI: 10.1093/cid/ciy025
  • 4. Henning D., Eade D., Langstone A., Bean-Hodges A., Marceglia A., Azzopardi P. Asymptomatic Mycoplasma genitalium infection amongst marginalised young people accessing a youth health service in Melbourne. Int J STD AIDS. 2014;25(4):299-302. DOI: 10.1177/0956462413502317
  • 5. Ahmadi M.H., Mirsalehian A., Gilani M.A.S., Bahador A., Talebi M. Improvement of semen parameters after antibiotic therapy in asymptomatic infertile men infected with Mycoplasma genitalium. Infection. 2018;46(1):31-38. DOI: 10.1007/s15010-017-1075-3
  • 6. Asenjo A., Kusters J.G., Severs T.T., Alós J.-I. Mycoplasma genitalium in Spain: prevalence of genital infection and frequency of resistance to macrolides. Enferm Infecc Microbiol Clin. 2018;36(3):169-171. DOI: 10.1016/j.eimc.2017.01.006
  • 7. Horner P.J., Blee K., Falk L., van der Meijden W., Moi H. 2016 European guideline on the management of nongonococcal urethritis. Int J STD AIDS. 2016;27(11):928937. DOI: 10.1177/0956462416648585
  • 8. Nye M.B., Harris A.B., Pherson A.J., Cartwright C.P. Prevalence of Mycoplasma genitalium infection in women with bacterial vaginosis. BMC Womens Health. 2020;20(1):62. DOI: 10.1186/s12905-020-00926-6
  • 9. Wiesenfeld H.C., Manhart L.E. Mycoplasma genitalium in women: current knowledge and research priorities for this recently emerged pathogen. J Infect Dis. 2017;216(Suppl. 2):S389-S395. DOI: 10.1093/infdis/jix198
  • 10. Tucker J.D., Ong J.J. Mycoplasma genitalium: an important sexually transmitted infection comes into focus. Sex Transm Infect. 2018;94(4):240-241. DOI: 10.1136/sextrans-2017-053517
  • 11. Ovens K.J., Reynolds-Wright J.J., Cross E.L.A., Rickwood L., Hassan-Ibrahim M.O., Soni S. High rates of treatment failure for Mycoplasma genitalium among men and women attending a sexual health clinic. BMJ Sex Reprod Heal. 2020;46(2):132-138. DOI: 10.1136/bmjsrh-2019-200384
  • 12. Shipitsyna E., Khusnutdinova T., Budilovskaya O., Krysanova A., Shalepo K., Savicheva A., et al. Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. Eur J Clin Microbiol Infect Dis. 2020;39(7):1221-1230. DOI: 10.1007/s10096020-03831-w
  • 13. Bernier A., Rumyantseva T., Reques L., Volkova N., Kyburz Y., Maximov O., et al. HIV and other sexually transmitted infections among female sex workers in Moscow (Russia): prevalence and associated risk factors. Sex Transm Infect. 2020;96(8):601-607. DOI: 10.1136/sextrans-2019-054299
  • 14. Workowski K.A., Bolan G.A. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. Morb Mortal Wkly Rep. 2015;64(RR03):1-137.
  • 15. Jensen J.S., Cusini M., Gomberg M., Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatology Venereol. 2016;30(10):16501656. DOI: 10.1111/jdv.13849
  • 16. Unemo M., Shipitsyna E., Savicheva A., Solokovskiy E., Ballard R., Domeika M., et al. Guidelines for the laboratory diagnosis of Mycoplasma genitalium infections in east European countries. Acta Derm Venereol. 2010;90(5):461467. DOI: 10.2340/00015555-0929
  • 17. Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Muzny C.A., Park I., et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Reports. 2021;70(4):1-187. DOI: 10.15585/mmwr.rr7004a1
  • 18. Diseases of the skin. Sexually transmitted infections. Dermatovenereology 2015. Federal Clinical Recommendations – M., Delovoj jekspress 2016. 768 p. Russian.
  • 19. Falk L., Fredlund H., Jensen J.S. Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex Transm Infect. 2003;79(4):318-319. DOI: 10.1136/sti.79.4.318
  • 20. van der Schalk T.E., Braam J.F., Kusters J.G. Molecular basis of antimicrobial resistance in Mycoplasma genitalium. Int J Antimicrob Agents. 2020;55(4):105911. DOI: 10.1016/j.ijantimicag.2020.105911
  • 21. Stafford I.A., Hummel K., Dunn J.J., Muldrew K., Berra A., Kravitz E.S., et al. Retrospective analysis of infection and antimicrobial resistance patterns of Mycoplasma genitalium among pregnant women in the southwestern USA. BMJ Open. 2021;11(6):e050475. DOI: 10.1136/bmjopen-2021-050475
  • 22. Hilmarsdóttir I., Arnardóttir E.M., Jóhannesdóttir E.R., Valsdóttir F., Golparian D., Hadad R., et al. Prevalence of Mycoplasma genitalium and antibiotic resistance-associated mutations in patients at a sexually transmitted infection clinic in Iceland, and comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium assays for diagnosis. Munson E., Ed. J Clin Microbiol. 2020;58(9):e01084-20. DOI: 10.1128/JCM.01084-20
  • 23. Fernández-Huerta M., Barberá M.J., Serra-Pladevall J., Esperalba J., Martínez-Gómez X., Centeno C., et al. Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review. Int J STD AIDS. 2020;31(3):190197. DOI: 10.1177/0956462419890737
  • 24. Korenromp E.L., Wi T., Resch S., Stover J., Broutet N. Costing of national STI program implementation for the global STI control strategy for the health sector, 20162021. PLoS One. 2017;12(Suppl. 1):e0170773. DOI: 10.1371/journal.pone.0170773
  • 25. Fernández-Huerta M., Barberá M.-J., Esperalba J., Fernandez-Naval C., Vall-Mayans M., Arando M., et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sex Transm Infect. 2020;96(4):300-305. DOI: 10.1136/sextrans-2019-054124
  • 26. Le Roy C., Hénin N., Bébéar C., Pereyre S. Evaluation of a commercial multiplex quantitative PCR (qPCR) assay for simultaneous detection of Mycoplasma genitalium and macrolide resistance-associated mutations in clinical specimens. J Clin Microbiol. 2017;55(3):978-979. DOI: 10.1128/JCM.02168-16
  • 27. Tabrizi S.N., Su J., Bradshaw C.S., Fairley C.K., Walker S., Tan L.Y., et al. Prospective evaluation of ResistancePlus MG, a new multiplex quantitative PCR assay for detection of Mycoplasma genitalium and macrolide resistance. J Clin Microbiol. 2017;55(6):1915-1919. DOI: 10.1128/JCM.02312-16
  • 28. Thellin O., Elmoualij B., Zorzi W., Jensen J.S., Close R., Deregowski V., et al. Four-color multiplex real-time PCR assay prototype targeting azithromycin resistance mutations in Mycoplasma genitalium. BMC Infect Dis. 2019;19(1):827. DOI: 10.1186/s12879-019-4424-2
  • 29. Le Roy C., Bébéar C., Pereyre S. Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance in Mycoplasma genitalium. J Clin Microbiol. 2020;58(Suppl. 2):e01478-19. DOI: 10.1128/JCM.01478-19
  • 30. Machalek D.A., Tao Y., Shilling H., Jensen J.S., Unemo M., Murray G., et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and metaanalysis. Lancet Infect Dis. 2020;20(11):1302-1314. DOI: 10.1016/S1473-3099(20)30154-7
  • 31. Guschin A., Ryzhikh P., Rumyantseva T., Gomberg M., Unemo M. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect Dis. 2015;15(1):40. DOI: 10.1186/s12879-015-0781-7
  • 32. Zubareva L.M., Eydel’shteyn I.A., Romanov A.V., Evstaf’ev V.V., Kozlov R.S. Clinical case of failure of josamycin in a patient with urethritis caused by Mycoplasma genitalium. Vestnik dermatologii i venerologii. 2018;94(4):5559. Russian. DOI: 10.25208/0042-4609-2018-94-4-55-59
  • 33. Shipitsyna E., Rumyantseva T., Golparian D., Khayrullina G., Lagos A.C., Edelstein I., et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. PLoS One. 2017;12(4):e0175763. DOI: 10.1371/journal.pone.0175763
  • 34. Shedko E.D., Khayrullina G.A., Goloveshkina E.N., Akimkin V.G. Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region. Eur J Clin Microbiol Infect Dis. 2021;40(7):1413-1418. DOI: 10.1007/s10096021-04170-0
  • 35. Romanova I.V., Kisina V.I., Khayrullina G.A., Frigo N.V., Zhukova O.V., Gushhin A.E. The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014-2018. Klinicheskaja dermatologija i venerologija. 2020;19(1):7-12. Russian. DOI: 10.17116/klinderma2020190117
  • 36. Zubareva L.M., Edelstein I.A., Rudneva N.S., Romanov A.V., Vlasova T.A., Lavrinenkova Y.V., et al. The rates of mutations associated with macrolide resistance in Mycoplasma genitalium among patients with non-gonococcal sexually transmitted infections in Smolensk and Tula. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(4):330-339. Russian. DOI: 10.36488/cmac.2019.4.330-339
  • 37. Edelstein I.A., Edelstein M.V., Romanov A.V., Zaitsev A.A., Rakovskaya I.V., Barkhatova O.I., et al. Four cases of resistance mutations in 23S rRNA gene in Mycoplasma pneumoniae isolated from the hospitalized military personnel. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2017;19(3):248-253. Russian.
  • 38. Romanov A.V., Kozlov R.S., Eidelstein I.A., Eidelstein M.V. A method for detecting mutations leading to resistance in Mycoplasma genitalium and Mycoplasma pneumoniae to macrolide antibiotics. Patent RU 0264612. Available at: www.fips.ru/fips_servl/fips_servlet?DB=RUPAT&rn=8176&DocNumber=02646123&TypeFile=html. Accesses at March 2022. Russian.
  • 39. Kuzmenkov A.Y., Vinogradova A.G., Trushin I.V., Avramenko A.A., Edelstein M.V., Dekhnich A.V., et al. AMRcloud: a new paradigm in monitoring of antibiotic resistance. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(2):119-124. Russian. DOI: 10.36488/cmac.2019.2.119-124
  • 40. Rudneva N., Sukhanova L., Dolgova T., Anisimova N., Gushchin A. Experience in organizing and conducting screening of pregnant women for sexually transmitted infections in the framework of the regional program of the Tula region. Vestnik novykh meditsinskikh tekhnologii. 2015;22(4):104-111. Russian. DOI: 10.12737/17033
  • 41. Read T.R.H., Fairley C.K., Murray G.L., Jensen J.S., Danielewski J., Worthington K., et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis. 2019;68(4):554-560. DOI: 10.1093/cid/ciy477
  • 42. Read T.R.H., Fairley C.K., Tabrizi S.N., Bissessor M., Vodstrcil L., Chow E.P.F., et al. Azithromycin 1.5 g over 5 days compared to 1g single dose in urethral Mycoplasma genitalium: impact on treatment outcome and resistance. Clin Infect Dis. 2017;64(3):250-256. DOI: 10.1093/cid/ciw719
  • 43. Sethi S., Zaman K., Jain N. Mycoplasma genitalium infections: current treatment options and resistance issues. Infect Drug Resist. 2017;10:283-292. DOI: 10.2147/IDR.S105469
  • 44. Couldwell D., Lewis D. Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistanceassociated mutations. Infect Drug Resist. 2015;8:147-161. DOI: 10.2147/idr.s48813
  • 45. Pereyre S., Gonzalez P., de Barbeyrac B., Darnige A., Renaudin H., Charron A., et al. Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob Agents Chemother. 2002;46(10):3142-3150. DOI: 10.1128/AAC.46.10.3142-3150.2002
  • 46. Haddad R., Golparian D., Lagos A., Jensen J.S. Macrolide and fluoroquinolone resistance in Mycoplasma genitalium in two Swedish counties. APMIS. 2017;126(2):123-127. DOI: 10.1111/amp.12792
Views
0 Abstract
0 PDF
0 Crossref citations
Shared